Navigation Links
Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
Date:8/4/2008

pical applications of its compounds to treat fungal, bacterial and inflammatory diseases. Anacor's most advanced product candidate is AN2690, a novel topical antifungal in development for the treatment of toenail onychomycosis, which is a fungal infection of the nail and nail bed. AN2690 is licensed to Schering-Plough under a worldwide development and commercialization agreement for all indications including the treatment of onychomycosis. Anacor also has a research and development collaboration with GlaxoSmithKline for the discovery, development, manufacture and worldwide commercialization of novel systemic therapeutics for viral and bacterial diseases utilizing Anacor's boron-based chemistry. For more information visit http://www.anacor.com.


'/>"/>
SOURCE Anacor Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Anacor to Present Clinical and Preclinical Data on Topical Anti-Inflammatory Candidates, AN2728 and AN2898, at the International Investigative Dermatology 2008 Conference
2. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
3. Anacor Files Registration Statement for Initial Public Offering
4. Anadys Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
5. VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
6. Onyx Pharmaceuticals to Present at Bank of America 2008 Specialty Pharmaceuticals Conference
7. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
8. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
9. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
10. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
11. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Louis, MO (PRWEB) August 21, 2014 ... full service biopharmaceutical contract development and manufacturing organization ... by Progenics Pharmaceuticals, Inc., an oncology company focused ... and treating cancer, to manufacture the anti-prostate specific ... PSMA ADC product candidate. Under the agreement ...
(Date:8/20/2014)... RALEIGH, N.C. , Aug. 20, 2014 /PRNewswire/ ... clinical research services located in Raleigh, ... Bradford Evans as Vice President of ... Administration, Brad will oversee all corporate processes, including ... to joining Clintrax Global, Brad worked as an ...
(Date:8/20/2014)... time, chemists have succeeded in measuring vibrational motion of ... study reveals how vibration of a single molecule differs ... The study was performed at the University of California, ... of Jyvskyl works as a visiting fellow under professor ... The second team was lead by Professor Eric O. ...
(Date:8/20/2014)... 20, 2014  Decision Resources Group finds that the vascular access ... , India and China ... roughly equal to the size of the United States ... will experience much faster growth as a result of strong economic ... Other key findings from Decision Resources Group,s coverage of the BRIC ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Clintrax Global, Inc. Announces Addition to Executive Team 2Seeing a molecule breathe 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3
... Life Sciences,Holdings, Inc. (Nasdaq: ADLS ), ... and commercialization of novel drugs in the,therapeutic ... today,announced that it was added to the ... reconstituted its comprehensive set of U.S. and,global ...
... 3 /Xinhua-PRNewswire-FirstCall/ -- Huifeng,Bio-Pharmaceutical Technology, Inc. (OTC ... of plant extracts and pharmaceutical raw materials,for ... in China,announced today that its company information ... Market Access Program, an information distribution,service that ...
... to offer choice of two distinct drugs on ... separate drug-eluting stent platforms, NATICK, ... today announced that the U.S. Food and Drug,Administration (FDA) has ... coronary artery disease. The,PROMUS Stent is a private-labeled XIENCE(TM) V ...
Cached Biology Technology:Advanced Life Sciences Added to Russell Microcap Index 2Advanced Life Sciences Added to Russell Microcap Index 3Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poor's Market Access Program 2Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System 2Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System 3Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System 4
(Date:8/20/2014)... University of Tennessee, Knoxville, research finds life can persist ... professor was part of a team that examined waters ... Antarctic ice sheet and found the extreme environment supports ... by Jill Mikucki and her colleagues has implications for ... in the solar system. The findings are published in ...
(Date:8/20/2014)... VALLEY, Calif., August 19, 2014 -- Bay Area Lyme ... diagnose and simple to cure, applauds new research published ... journal Ticks and Tick-borne Diseases . The ... Northwest California are active throughout the year, making the ... by researchers at California Department of Public Health (CDPH) ...
(Date:8/20/2014)... chili pepper causes a burning spiciness that is irresistible ... chili pepper,s effect are using their findings to develop ... which can be caused by inflammation or other problems. ... being tested in clinical trials, in ACS, Journal ... explain that decades ago, scientists had pegged a compound ...
Breaking Biology News(10 mins):University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3
... by LSU Associate Professors of Biological Sciences Fernando Galvez and ... and laboratory study showing the effects of the Deepwater Horizon ... , The study, funded in part by the National Science ... is being published in the journal Proceedings of the ...
... Alzheimer,s disease rises and falls in the spinal fluid in ... Washington University School of Medicine in St. Louis have found. ... and reinforces a link between increased Alzheimer,s risk and inadequate ... brain,s relative inactivity during sleep may provide an opportunity to ...
... Steve Bergens and his graduate student Jeremy Johns ... to revolutionise the chemical industry by reducing its ... Their findings were published in a top international ... the chemical industry with a potential solution to ...
Cached Biology News:LSU researchers find impact of oil spill in marsh fish species 2Marker for Alzheimer's disease rises during day and falls with sleep 2Marker for Alzheimer's disease rises during day and falls with sleep 3Catalyst discovery has potential to revolutionize chemical industry 2
Piperazine-N',N'-bis(2-ethanesulfonic acid), monosodium salt...
... receptors constitute the principal excitatory ... classes of glutamate receptors exist: ... Ionotropic glutamate receptors are oligomeric ... NMDA1-3, KAI-2) which comprise ligand-gated ...
Recommended fro Western blotting application...
... Anti-Krueppel-like factor 15 (KLF15) KLF15 is ... found abundantly expressed in the liver, kidneys, ... NP_054798 Specificity: Polyclonal antibody produced in ... to a region of human KLF15 with ...
Biology Products: